Lilly and Indiana University Forge Historic $40 Million Partnership to Revolutionize Clinical Trials and Expand Access to Cutting-Edge Therapies for Hoosiers Eli Lilly and Company and Indiana University (IU) have announced a transformative five-year partnership valued at up to $40…
Bayer Launches Pivotal Phase III SUNFLOWER Trial to Evaluate Mirena® for the Treatment of Nonatypical Endometrial Hyperplasia Bayer, a global pioneer in women’s healthcare, has officially initiated SUNFLOWER (Study of Understanding NAEH – treatment Efficacy of Levonorgestrel – IUS in…
AdvanCell Launches Pivotal Phase 2 Expansion Trial of ADVC001, a First-in-Class Targeted Alpha Therapy for Metastatic Prostate Cancer AdvanCell, a clinical-stage radiopharmaceutical company at the forefront of developing next-generation targeted alpha therapies (TATs) for oncology, has announced the initiation of…
Samsung Bioepis Launches Denosumab Biosimilars OBODENCE™ and XBRYK™ in Europe to Improve Access and Patient Outcomes Samsung Bioepis Co., Ltd., a global biopharmaceutical company recognized for its innovative work in developing biosimilars across multiple therapeutic areas, today announced the commercial…
AltPep Corporation Presents New Preclinical Data Demonstrating SOBIN-AD Peptide Improves Cognition in Early and Symptomatic Alzheimer’s Disease Models at CTAD 2025 AltPep Corporation, a privately held biotechnology company dedicated to developing early disease-modifying therapies and innovative detection tools for amyloid-related…
Mirum Pharmaceuticals Enrolls First Participant in BLOOM Phase 2 Study Evaluating MRM-3379 for Fragile X Syndrome Mirum Pharmaceuticals, Inc., a biopharmaceutical company focused on developing and delivering innovative therapies for rare diseases, announced today a key milestone in its development…
Blue Lake Biotechnology Announces FDA Clearance to Resume Enrollment of RSV-Negative and Younger Toddlers in Phase 1/2a Clinical Trial of BLB201 Blue Lake Biotechnology, Inc., a clinical-stage company pioneering intranasal vaccines based on the parainfluenza virus 5 (PIV5) vector platform,…
Contineum Therapeutics Reports Topline Data From Phase 2 VISTA Trial Evaluating PIPE-307 in Relapsing-Remitting Multiple Sclerosis Contineum Therapeutics, Inc. (NASDAQ: CTNM) (“Contineum” or the “Company”), a clinical-stage biopharmaceutical organization advancing differentiated therapies across neuroscience, inflammation, and immunology (NI&I), announced the…
Phase 1 Trial Reveals Promising Early Activity for Tinostamustine in Glioblastoma Purdue Pharma L.P. (“Purdue”) has announced encouraging preliminary data from its ongoing Phase 1 clinical study evaluating tinostamustine in patients with MGMT promoter-unmethylated (uMGMT) glioblastoma (GBM), an especially aggressive…
Parse Biosciences Unveils Breakthrough FFPE-Compatible Barcoding Technology, Enabling Whole-Transcriptome Single-Cell Analysis from Archival Tissues Parse Biosciences, a global leader in scalable and accessible single-cell sequencing technologies, has announced a transformative advancement that stands to reshape how researchers analyze archived biological…
Single-tablet regimen shows non-inferior efficacy and strong safety in virologically suppressed adults with HIV-1. Gilead Sciences, Inc. (NASDAQ: GILD) has announced encouraging topline results from its Phase 3 ARTISTRY-1 clinical trial, marking an important milestone in the company’s ongoing efforts…
Samsung Epis Holdings Launches Epis NexLab to Pioneer Next-Generation Biotech Platforms and Drive Global Innovation Samsung Epis Holdings Co., Ltd. has officially announced the establishment of Epis NexLab Co., Ltd., a wholly owned subsidiary dedicated to advancing next-generation biotechnology platforms.…